Mesoblast desire for product entry to be accelerated

Company News

by Rachael Jones

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is looking to accelerate their entry for product MPC-150-IM into the cardiovascular market after an successful set of on-going trials.

Their phase 3 and phase 2b trails are looking at moderate-to-severe and end stage advanced chronic heart failure patients.

Their product helps reduce damaging inflammation and builds cardiac repair.

Indications are that there are major unmet medical needs due to the high death rates despite existing therapies

The Data Monitoring Committee (DMC) recommended continuation of the trial without modification.

Shares in Mesoblast Limited (ASX:MSB) down 1.88% to $1.57

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.